This cross-sectional study aimed to analyse myocardial deformation in patients with Fabry disease (FD) in order to evaluate speckle tracking as a method for non-invasive determination of myocardial fibrosis. Myocardial fibrosis is common in Fabry cardiomyopathy and is associated with disease progression and severe prognosis.
Introduction
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of a-galactosidase A leading to a multisystemic disease affecting the kidneys, nervous system, and heart. 1, 2 The cardiac pathogenic correlate is the accumulation of globotriaosylceramides in cells, especially in myocytes, causing left-ventricular (LV) hypertrophy and finally leading to myocardial replacement fibrosis. 3 -6 The main cardiac symptoms are arrhythmias and heart failure, which are mainly responsible for reduced life expectancy in FD. 7, 8 Myocardial replacement fibrosis is a typical feature of an advanced Fabry cardiomyopathy. The non-invasive gold-standard to assess this kind of fibrosis is magnetic resonance imaging † The first two authors contributed equally.
(MRI) using the late-enhancement (LE) technique. 9 Obviously, this non-contracting fibrosis should have an impact on myocardial function. So far, the impact of replacement fibrosis on regional myocardial function was never systematically investigated. Two-dimensional (2D) speckle-tracking imaging is a non-invasive echocardiographic tool for the assessment of regional myocardial function. 10 This technique is widely available, highly reproducible, and easy applicable. In addition, as some FD patients have contraindications against MRI and LE imaging, echocardiography is the only available diagnostic tool to assess myocardial morphology and function. The aim of this cross-sectional study was to investigate the impact of myocardial fibrosis on regional myocardial deformation in a large cohort of FD patients. It was hypothesized that 2D speckle-tracking imaging can indirectly assess the functional abnormalities related to fibrosis and thus will be of value to stage Fabry cardiomyopathy.
Methods

Study population
In total, 162 patients were screened at their first visit in the Fabry centre in Wuerzburg. According to this, none of the patients were receiving enzyme replacement therapy (ERT). Criteria for inclusion were (i) genetically proofed FD, (ii) ability for MRI with contrast agent, (iii) ability for echocardiography, (iv) absence of coronary artery disease, and (v) informed consent for examinations and participation in the study. Overall, 101 consecutive patients (59 females) were included in this study. Reasons for exclusion (n ¼ 61) were all accorded to contraindications for MRI such as claustrophobia, hip implant, pacemakers, or severe renal dysfunction. At this point of time, gadolinium-contrast MRI of the heart for the assessment of fibrosis and speckle-tracking imaging for the quantification of systolic longitudinal strain were performed in all patients within 2 days. In addition, the standard data were obtained from echocardiography as well as clinical examination in the context of a standard clinical investigation programme for Fabry patients. According to the Declaration of Helsinki, written informed consent of all patients or their guardians was obtained.
Patients were analysed according to the amount of LE in the LV myocardium. A value of ≥2% was chosen to distinguish between patients with mild and severe LE according to the quartiles of distribution of LE. 51% of our patients showed no LE in MRI (second quartile). As the third quartile was at 1.9% a cut off value of 2% was used.
Magnetic resonance imaging and assessment of fibrosis
Magnetic resonance imaging of the heart was performed after the intravenous injection of gadopentetate dimeglumine 0.2 mmol/kg (Magnevist, Schering AG, Berlin, Germany) on a 1.5 T scanner (Magnetom Symphony Quantum, Siemens Medical Systems, Erlangen, Germany). Pictures were acquired with inverse recovery sequences (8 mm slice thickness, breath hold, field of view 240 × 320 mm 2 , matrix size 165 × 256, repetition time 7.5 ms, echo time 3.4 ms, flip angle 258). All consecutive short-axis slices were used for manual measuring the area with pathological mid-or transmyocardial LE. The sum of areas was multiplied with the slice thickness and then set in relation to the LV myocardium volume. Every segment (17-segment model) was scanned separately for the occurrence of pathological LE.
Standard echocardiographic measurements
Left ventricular parasternal long-axis images with M-mode echocardiography [Vivid 7 (3.5 MHz), GE Vingmed Ultrasound AS, Horten, Norway] were used for the determination of end-diastolic and endsystolic dimensions as well as LV septal and posterior wall thickness. Additionally, left atrial diameter and the diameter of the aortic root were measured. By the application of Simpson's formula, LV ejection fraction (EF) was calculated based on the 2-and 4-chamber views. Blood-pooled pulsed Doppler of the mitral valve inflow was used to quantify the ratio of early-to-late (E/A) diastolic flow velocity and the deceleration time. The transmitral flow was determined by placing the Doppler window between the tips of mitral valve leaflets and peak flow velocities in early (E wave) and late (A wave) systole were measured. In patients in which the E/A ratio was not sufficient to quantify diastolic function, the difference between the duration of blood flow in pulmonary veins and the duration of blood flow in the left ventricle (both after atrial contraction) was calculated, indicating elevated filling pressure with values .30 ms. Additionally, tissue Doppler was performed for measuring the ratio between early transmitral flow and peak early tissue Doppler velocity (E/e ′ ). Measurements of the movement of septal and lateral valve ring were averaged over three cycles. Using those parameters, diastolic function was graded either as normal, relaxation abnormalities (grade 1), pseudonormal (grade 2), or restrictive (grade 3).
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The standard apical views of the LV were acquired for off-line quantification of myocardial deformation values by 2D speckle tracking using ECHO-Pac Software (GE Vingmed Ultrasound AS). After the manual selection of the region of interest (ROI), speckles were assumed automatically and then confirmed by the user. By the semiautomatic post-processing longitudinal systolic strain of the 17 LV segments were extracted. Global strain is presented as the mean value of all valid segments. Intra-and interobserver variability of 2D speckletracking longitudinal strain, expressed as a percentage of the average, was 9.8 and 11.4% for single-segment longitudinal strain as previously described in our laboratory. 12 Global strain in our measurements
showed an intra-observer variability of 1.1 + 0.9% and an interobserver variability of 1.3 + 1.2%.
Statistical analysis
All values are presented as the mean + SD or as the absolute number.
Differences between two groups were tested using the paired or unpaired t-test if normal distribution could be assumed. Otherwise, the Wilcoxon rank-sum test was performed. For categorical data, the chi-squared test or the Fisher's exact test was used. All differences were tested two-sided. Larger numbers of groups were tested using two-way analysis of variance. Receiver operating characteristic (ROC) analysis and multivariate logistic regression analysis were performed to evaluate the ability of longitudinal strain values to distinguish between patients with different amounts of LE. Analysis of correlation was performed with the Pearson correlation coefficient. To differentiate the value with the highest impact multivariate logistic regression analysis was performed. P-values of ,0.05 are considered as indicating statistical significance. Data were analysed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).
Results
The clinical data of all patients, separated by gender, are presented in Table 1 . According to the X-linked inheritance, male patients are significantly younger at first presentation. Data in parenthesis are % of total. GI, gastrointestinal; TIA, transitory ischaemic attack; SBP, systolic blood pressure; DBP, diastolic blood pressure; AT, angiotensin; ACE, angiotensin converting enzyme; GFR, glomerular filtration rate; NYHA, New York Heart Association; NT-proBNP, N-terminal of brain natriuretic peptide; Hb, haemoglobin.
The assessment of kidney function showed the lower measured glomerular filtration rate (the 99 TC DTPA tracer method) and higher serum creatinine concentrations in conjunction with the higher prevalence of proteinuria in male patients. Systolic and diastolic blood pressures were not significantly different between males and females.
Assessment of fibrosis
Among all patients, 52 [51% (female 44.1%; male ¼ 61.9%; P ¼ 0.11)] showed mid-and transmyocardial LE with a mean volume of 1.2 + 1.8% of the LV mass. This total amount of LE was much less than the reported 7.7% in the study by Moon et al. 9 as we investigated a large cross-sectional cohort in which also very early stages of the disease were included. Female patients with LE-positive myocardium (n ¼ 26) presented smaller volumes of LE (0.8 + 1.3%) than male patients (n ¼ 26; 1.6 + 2.3%; P ¼ 0.02).
In both genders, the pathological LE was limited to posterior and lateral segments, with different distensions towards the apex but not reaching the apical segments. Only four patients did not present the typical predominant LE pattern in the posterolateral region of the LV. None of the patients showed subendocardial LE.
Among patients with mild LE (less than 2% fibrosis; n ¼ 30), no difference was detected between females (n ¼ 18) and males (1.2 + 0.5% vs. 1.6 + 0.3%). In patients with severe LE (more than 2% LE; n ¼ 22), females had 2.4 + 1.3% (n ¼ 8) and males 4.4 + 2.1% LE (P ¼ 0.01). Patients with LE-positive segments had significantly more cardiac events in the clinical history ( 
Echocardiographic data
The results from the standard echocardiography divided for the two groups with and without LE are presented in Table 3 . Ejection fraction and fractional shortening were in normal range in both groups. Left ventricular septal and posterior wall thickness were higher in patients with LE. Diastolic function was normal in 20 (41%) patients without fibrosis and in 10 patients (19%) with fibrosis (P , 0.001). Twelve (12%) patients showed inferolateral wall motion abnormalities in 2D echocardiography [group no LE (n ¼ 49) 6%; group LE (n ¼ 52) 17%; P ¼ 0.083].
Myocardial deformation imaging
Global peak systolic strain was 217.7 + 3.2% in female (n ¼ 59) and 215.4 + 3.6% in male patients (n ¼ 42; P , 0.001). Divided into groups with and without myocardial fibrosis, global peak systolic strain was lower in those with myocardial fibrosis (n ¼ 52; 214.8 + 3.5%) compared with those without fibrosis (n ¼ 49; 218.9 + 2.1%; P , 0.001). The subgroup with mild fibrosis presented higher global longitudinal strain than the subgroup with severe fibrosis [group mild LE (n ¼ 30) 215.5 + 3.2%; group severe LE (n ¼ 22) 213.7 + 3.5%].
For the interaction between the total amount of LE and global myocardial deformation, a positive correlation was found (r ¼ 0.54; P , 0.001), indicating that higher rates of fibrosis are associated with lower global deformation values. Strain values separated by segments in the different LE groups are shown in Table 4 .
When evaluating the influence of all segmental strain values on global systolic strain, only basal lateral and basal posterior segments had a significant influence ( Table 5) . Comparing the mean difference of segmental strain with global strain, no LE group (n ¼ 49) showed no segment with significant outstanding negative influence, but basal inferior segment with positive influence (+2.4 + 3.8%; P , 0.001). The same positive influence on global strain was detected in the mild LE group (n ¼ 30, basal inferior strain: +2.1 + 4.5%) and severe LE group (n ¼ 22, basal inferior strain: +3.3 + 3.6%). In contrast, in the groups with LE basal lateral wall segment [group mild LE (n ¼ 30) 24.8 + 9.3%; P ¼ 0.009, group severe LE (n ¼ Speckle tracking in Fabry disease 1.1%; P ¼ 0.001; group severe LE (n ¼ 22) 22 0.7 + 7.9%; P ¼ 0.03] showed negative influence on global strain. All values are presented in Table 5 . Figure 1 shows examples of deformation imaging in parallel to MRI images for selected patients with different stages of the cardiomyopathy. Figure 2 presents strain curves from a case with fibrosis compared with a case without fibrosis next to each patients MRI of basal myocardium.
Stratifying the subgroups by gender, no significant differences were found for global longitudinal systolic strain in groups without LE [female (n ¼ 33) 219.1 + 2.3%; male (n ¼ 16) 218.5 + 1.7%; P ¼ 0.41] and mild LE [female (n ¼ 10) 216.2 + 3.8%; male (n ¼ 20) 214.6 + 1.9%; P ¼ 0.15]. In contrast, the group with severe LE showed a significant difference in global strain dependent on gender [female (n ¼ 7) 215.8 + 2.3%; male (n ¼ 15) 212.5 + 3.6%; P ¼ 0.02]. The global systolic strain values of patients in subgroups are shown in Table 4 .
Patients with LE had significant thicker walls and a larger LA diameter.
With higher amounts of LE, the symmetrical pattern of LV hypertrophy changed to an asymmetrical pattern: the ratio of posterior to septal wall thickness in patients without LE (n ¼ 49) was higher (0.99 + 0.04) than in those with mild LE (n ¼ 30; 0.97 + 0.09) and with severe LE (n ¼ 22; 0.92 + 0.09; P , 0.001). A negative correlation for the amount of LE and the ratio of wall thickness could be demonstrated (r ¼ 20.39; P , 0.001).
To evaluate the best echocardiographic parameter for the assessment of myocardial LE, a multivariate logistic proportional regression analysis with fixed adjustment for age and sex was performed for all myocardial segments, as well as for EF, fractional shortening, and the ratio of posterior to septal wall thickness. Results of the regression analysis are presented in Table 6 . This analysis suggests that systolic strain in basal posterior or lateral segments is the most powerful predictor for LE (odds ratio ¼ 1. All values presented in % + SD. P-values are calculated by the unpaired t-test or by the non-parametric tests if necessary. ANOVA shows the differences for each segment compared between all three fibrosis groups.
strain was able to detect the hearts being LE positive (AUC ¼ 0.869; P , 0.001) (Figures 3 and 4) . In contrast, the ratio of posterior to septal wall thickness was only able to detect LE with 80% sensitivity and a specificity of 52% (AUC ¼ 0.701; P , 0.001).
The correlation between global systolic strain and the amount of fibrosis was 0.54 (P , 0.001). Additionally, the correlation of the amount of LE with LV mass (r ¼ 0.38; P , 0.001), wall diameter of the posterior wall (r ¼ 0.48; P , 0.001), or diastolic function (r ¼ 0.11; P ¼ 0.274) shows that the identification of myocardial fibrosis is not possible by those parameters.
As systolic strain in the basal posterior and lateral segment was best correlated with the occurrence of LE in MRI, a cut-off value for systolic strain for the detection of LE was evaluated. Thus, strain values in one of these segments lower than 212.5% indicated LE with a specificity of 97% and a sensitivity of 90%. In addition, patients with strain in those segments higher than 216.5% indicated no pathological LE (100% specificity and 89% sensitivity).
Discussion
The aim of this study was to investigate the influence of myocardial LE on deformation values by the use of 2D speckle-tracking imaging in patients with FD. The results are three-fold: first, the presence of myocardial replacement fibrosis in the LV is associated with lower deformation values. Second, the total amount of replacement fibrosis has an impact on regional systolic strain in the ROI and in addition also on the global longitudinal systolic strain of the LV. And third, the lower longitudinal systolic strain is mainly found in the typical location for LE, the basal posterior and lateral LV segments. We conclude that 2D speckle-tracking imaging is an easy, reliable, and reproducible echocardiographic tool for the non-invasive evaluation of LE-related functional abnormalities in patients with FD.
The Fabry cardiomyopathy
Well-established morphologic features of the Fabry cardiomyopathy are concentric LV hypertrophy and replacement fibrosis. Systolic function is represented by preserved EF and diastolic function by filling abnormalities. 3, 9, 13, 14 The current study is the first to evaluate systematically regional function abnormalities in a large cohort of FD patients by the use of 2D speckle-tracking imaging. It could be shown that a typical regional deformation pattern can be detected in advanced stages of the Fabry cardiomyopathy with the lowest values in the basal posterior and lateral LV segments. This pathological region is known from MRI LE imaging and thus most likely related to replacement fibrosis. These regional functional abnormalities can be detected even in patients with normal global EF. Thus, EF is not helpful for the routine echocardiographic evaluation of LV systolic function in Fabry cardiomyopathy and 2D speckle-tracking imaging should be favoured. Using this technique, the impact of fibrosis on both, global LV function (by global longitudinal strain) and regional myocardial function (by longitudinal strain in the basal posterolateral segments), can be assessed. In this context, the low regional longitudinal strain appears to be related mainly to replacement fibrosis, whereas the reduction in global systolic strain is due to the interaction of LV hypertrophy, interstitial and replacement fibrosis, and even subclinical atherosclerotic alterations. 15 -17 Left ventricular mass and posterior wall diameter and diastolic function are not usable as markers for myocardial fibrosis. The impact of impaired wall stress on systolic function could not be answered by the data presented in this study. As expected, the hearts with proven replacement fibrosis showed echocardiographic left atrial enlargement, an asymmetrical hypertrophy pattern and pronounced diastolic filling abnormalities in addition to the deformation abnormalities. Additionally, patients with myocardial LE had more cardiac events in the past and in general displayed a higher New York heart association functional class. Further investigation of clinical presentation according to the subgroups of LE was not performed because of the number of events getting too low for useful analysis. 
Clinical impact
Tissue Doppler-based strain rate imaging has already be proven to detect sensitive systolic functional abnormalities in the Fabry cardiomyopathy. 9,13,19 -21 However, this technique is timeconsuming, difficult for post-processing, and not everywhere available. In contrast, 2D speckle-tracking imaging is easy and fast during post-processing and meanwhile everywhere available. 10 In addition, even 2D grey-scale data, acquired in the era where these new echocardiographic tools were not available, can be post-processed for the quantification of regional myocardial deformation. Longitudinal changes of regional myocardial function can be obtained, both for the evaluation of the natural history and for the impact of ERT.
Although LE imaging is the non-invasive gold standard for the evaluation of replacement fibrosis, 9 it cannot be performed in all FD patients. For patients with end-stage renal disease, contrast agents are contraindicated as well as patients with an implanted cardiac defibrillator or pacemaker cannot be examined by MRI. 21 Thus, in all these groups of patients, 2D speckle-tracking imaging is the only option for the indirect assessment of LE. It is important to evaluate the presence or the absence of replacement fibrosis especially in these advanced stages of the disease and it has impact on subsequent treatment with enzyme replacement. 22 During an individual evaluation of a potential Fabry cardiomyopathy patient with 2D speckle-tracking imaging, a systolic longitudinal strain value of more than 16.5% in typical location makes replacement fibrosis extremely unlikely. Vice versa, a value of lower than 12.5% is very often related to replacement fibrosis and results in the diagnosis of advanced stage of the disease. When evaluating all established echocardiographic parameters and the new regional deformation parameter, it became evident that the amount of systolic strain in the ROI is the best parameter for the detection or exclusion of replacement fibrosis in a Fabry heart.
Study limitations
It is important to mention the limitations of 2D speckle-tracking imaging: the measurements are dependent on the selection of the ROI. The try for standardization with defined cutting planes in echocardiography and the precise selection of the myocardium promotes higher reproducibility but still lacks of exact definitions. In addition, the technique is dependent on the software used for calculation provided by different vendors. But, in general, Speckle tracking in Fabry disease longitudinal strain shows the best reproducibility compared with circumferential and radial strain. 23 Therefore, it is important to know that the indirect detection of fibrosis by 2D speckle tracking might be possible also with a different ultrasound equipment. However, in these days, the absolute values cannot be compared between the different ultrasound machines. Because of ethical reasons, myocardial biopsies could not be obtained for the distinct proof of the fibrosis. However, even with biopsies, only local tissue information can be achieved.
The impact of ERT and other medication on myocardial deformation and the amount of fibrosis was not subject of the investigation. Consequently, patients were not separated by their status of therapy. This should be done in further longitudinal studies.
Conclusions
In FD myocardial replacement, fibrosis is associated with low myocardial deformation. Loss of regional deformation is mainly present in segments with LE in MRI; hence, it is likely caused by myocardial fibrosis. Speckle tracking can be used as a tool for the indirect evaluation of fibrosis in the Fabry cardiomyopathy.
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